Biotech has joined the new war on infectious diseases—for sound business reasons. The markets are good, of course since the need for drugs that work on the increasingly resistant bugs is growing.
Moreover, the genomics companies are promising to pinpoint a wealth of vulnerable targets for drug makers to attack. The opportunity...